CCAAT/Enhancer binding protein β controls androgen-deprivation-induced senescence in prostate cancer cells.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8711562 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5594 (Electronic) Linking ISSN: 09509232 NLM ISO Abbreviation: Oncogene Subsets: MEDLINE

Publication: <2002->: Basingstoke : Nature Publishing Group
Original Publication: Basingstoke, Hampshire, UK : Scientific & Medical Division, MacMillan Press, c1987-

Androgens/*deficiency ; Androgens/*pharmacology ; CCAAT-Enhancer-Binding Protein-beta/*metabolism ; Cellular Senescence/*drug effects ; Gene Expression Regulation, Neoplastic/*drug effects ; Prostatic Neoplasms/*pathology; Apoptosis/drug effects ; Blotting, Western ; CCAAT-Enhancer-Binding Protein-beta/genetics ; Cell Proliferation/drug effects ; Chromatin Immunoprecipitation ; Flow Cytometry ; Fluorescent Antibody Technique ; Humans ; Immunoenzyme Techniques ; Male ; Promoter Regions, Genetic/genetics ; Prostatic Neoplasms/drug therapy ; Prostatic Neoplasms/metabolism ; RNA, Messenger/genetics ; Real-Time Polymerase Chain Reaction ; Reverse Transcriptase Polymerase Chain Reaction ; Transcription, Genetic/drug effects ; Tumor Cells, Cultured

The processes associated with transition to castration-resistant prostate cancer (PC) growth are not well understood. Cellular senescence is a stable cell cycle arrest that occurs in response to sublethal stress. It is often overcome in malignant transformation to confer a survival advantage. CCAAT/Enhancer Binding Protein (C/EBP) β function is frequently deregulated in human malignancies and interestingly, androgen-sensitive PC cells express primarily the liver-enriched inhibitory protein isoform. We found that C/EBPβ expression is negatively regulated by androgen receptor (AR) activity and that treatment of androgen-sensitive cell lines with anti-androgens increases C/EBPβ mRNA and protein levels. Accordingly, we also find that C/EBPβ levels are significantly elevated in primary PC samples from castration-resistant compared with therapy-naive patients. Chromatin immunoprecipitation demonstrated enhanced binding of the AR to the proximal promoter of the CEBPB gene in the presence of dihydroxytestosterone. Upon androgen deprivation, induction of C/EBPβ is facilitated by active transcription as evident by increased histone 3 acetylation at the C/EBPβ promoter. Also, the androgen agonist R1881 suppresses the activity of a CEBPB promoter reporter. Loss of C/EBPβ expression prevents growth arrest following androgen deprivation or anti-androgen challenge. Accordingly, suppression of C/EBPβ under low androgen conditions results in reduced expression of senescence-associated secretory genes, significantly decreased number of cells displaying heterochromatin foci and increased numbers of Ki67-positive cells. Ectopic expression of C/EBPβ caused pronounced morphological changes, reduced PC cell growth and increased the number of senescent LNCaP cells. Lastly, we found that senescence contributes to PC cell survival under androgen deprivation, and C/EBPβ-deficient cells were significantly more susceptible to killing by cytotoxic chemotherapy following androgen deprivation. Our data demonstrate that upregulation of C/EBPβ is critical for complete maintenance of androgen deprivation-induced senescence and that targeting C/EBPβ expression may synergize with anti-androgen or chemotherapy in eradicating PC.

Mod Pathol. 2006 Oct;19(10):1339-43. (PMID: 16799475)
Carcinogenesis. 2008 Jun;29(6):1148-56. (PMID: 18487223)
Prostate. 2007 Aug 1;67(11):1238-46. (PMID: 17570496)
Mol Cancer Res. 2007 Jul;5(7):737-48. (PMID: 17606477)
Br J Cancer. 2008 Jan 29;98(2):245-9. (PMID: 18182995)
Cell. 2008 Jun 13;133(6):1006-18. (PMID: 18555777)
Prostate. 2008 Sep 1;68(12):1362-71. (PMID: 18512730)
Prostate. 2009 Sep 15;69(13):1435-47. (PMID: 19489038)
PLoS One. 2008;3(11):e3645. (PMID: 18997859)
Cancer Res. 2008 Oct 1;68(19):7864-71. (PMID: 18829542)
Proc Natl Acad Sci U S A. 2009 Oct 6;106(40):17031-6. (PMID: 19805069)
Nat Protoc. 2009;4(12):1798-806. (PMID: 20010931)
Nat Rev Cancer. 2010 Jan;10(1):51-7. (PMID: 20029423)
Annu Rev Pathol. 2010;5:99-118. (PMID: 20078217)
Oncogene. 2010 Feb 4;29(5):723-38. (PMID: 19901962)
Proc Natl Acad Sci U S A. 2011 Jan 25;108(4):1531-6. (PMID: 21205896)
Blood. 2011 Apr 14;117(15):4085-94. (PMID: 21346255)
Int J Oncol. 2011 Jun;38(6):1489-500. (PMID: 21455575)
Neoplasia. 2011 Jun;13(6):526-36. (PMID: 21677876)
Nucleic Acids Res. 2011 Jul;39(12):e82. (PMID: 21493687)
Cancer Res. 2011 Aug 1;71(15):5154-63. (PMID: 21697285)
Cancer Cell. 2011 Oct 18;20(4):457-71. (PMID: 22014572)
Nature. 2012 Jul 12;487(7406):239-43. (PMID: 22722839)
Nature. 2012 Nov 1;491(7422):114-8. (PMID: 23000899)
Cell Death Dis. 2012;3:e446. (PMID: 23254289)
Cancer Cell. 2013 Jan 14;23(1):35-47. (PMID: 23260764)
Prostate. 2013 Mar;73(4):337-45. (PMID: 22911222)
PLoS One. 2013;8(6):e68003. (PMID: 23840802)
Mol Cell Biol. 2013 Aug;33(16):3242-58. (PMID: 23775115)
J Immunol. 2013 Sep 1;191(5):2837-46. (PMID: 23894194)
Nucleic Acids Res. 2014 Jan;42(2):999-1015. (PMID: 24163104)
Nucleic Acids Res. 1999 Nov 15;27(22):4517-25. (PMID: 10536163)
Mol Endocrinol. 2000 May;14(5):753-60. (PMID: 10809237)
Genes Dev. 2000 Aug 1;14(15):1920-32. (PMID: 10921906)
J Cell Sci. 2000 Oct;113 ( Pt 20):3613-22. (PMID: 11017877)
Mol Med. 2000 Sep;6(9):736-49. (PMID: 11071269)
Biol Pharm Bull. 2000 Dec;23(12):1424-9. (PMID: 11145170)
Cancer Res. 2001 Mar 1;61(5):2328-34. (PMID: 11280806)
Clin Cancer Res. 2001 Mar;7(3):544-50. (PMID: 11297246)
Mol Cell. 2002 Mar;9(3):601-10. (PMID: 11931767)
Carcinogenesis. 2002 Aug;23(8):1289-96. (PMID: 12151346)
Cell. 2003 Jun 13;113(6):703-16. (PMID: 12809602)
N Engl J Med. 2003 Jul 24;349(4):366-81. (PMID: 12878745)
Mol Cell Biol. 1995 Sep;15(9):4971-9. (PMID: 7651415)
Prostate. 1996 Apr;28(4):251-65. (PMID: 8602401)
Adv Pharmacol. 1996;35:281-306. (PMID: 8920208)
Mol Endocrinol. 1998 Nov;12(11):1749-63. (PMID: 9817600)
Clin Cancer Res. 1999 May;5(5):977-83. (PMID: 10353729)
Br J Cancer. 1999 May;80(3-4):546-55. (PMID: 10408865)
Blood. 1999 Jul 15;94(2):560-71. (PMID: 10397723)
J Biol Chem. 1999 Sep 10;274(37):26591-8. (PMID: 10473624)
Carcinogenesis. 2005 Apr;26(4):793-801. (PMID: 15661808)
EMBO J. 2005 Sep 21;24(18):3301-12. (PMID: 16107878)
Mol Cancer Res. 2005 Oct;3(10):585-96. (PMID: 16254192)
Cancer Res. 2006 Jan 15;66(2):794-802. (PMID: 16424011)
Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1870-5. (PMID: 16439483)
Cell Cycle. 2006 May;5(9):922-5. (PMID: 16687914)
Cell. 2008 Jun 13;133(6):1019-31. (PMID: 18555778)
Neoplasia. 2007 Feb;9(2):166-80. (PMID: 17356713)

P30 CA006973 United States CA NCI NIH HHS; T32 CA060441 United States CA NCI NIH HHS; T32 CA60441 United States CA NCI NIH HHS

0 (Androgens)
0 (CCAAT-Enhancer-Binding Protein-beta)
0 (CEBPB protein, human)
0 (RNA, Messenger)

Date Created: 20150317 Date Completed: 20160308 Latest Revision: 20181113

20231215

PMC4573387

10.1038/onc.2015.41

25772238